Art. -Nr.: HY-13988

AT-56

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC₅₀ of 95 μM and K_i of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD₂.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.75%
CAS. Nr.: 162640-98-4
Formel: C₂₅H₂₇N₅
Molecular Weight:397.52

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

AT-56 Chemical Structure

CAS. Nr.: 162640-98-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) AT-56

Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]

Customer Validation & Images

RT-PCRCell Migration/Invasion AssayIn Vivo Efficacy StudyIHC

RT-PCR
Cell Migration/Invasion Assay
In Vivo Efficacy Study
IHC

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 95 μM (L-PGDS); Ki: 75 μM (L-PGDS)^[1]

In Vitro

AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD₂ in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC₅₀ of about 3 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AT-56 (?1-30 mg/kg; p.o.) suppresses the PGD₂ production in the stab-wounded brain^[1].
AT-56 (1-10 mg/kg; p.o.) suppresses the L-PGDS-mediated allergic airway inflammation in mice^[1].
AT-56 (10 mg/kg; p.o.) exhibits C_max (2.15 μg/ml), half-life (1.71 h) and high oral bioavailability (82%)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury^[1]
Dosage:

0, 1, 3, 10, 30 mg/kg
Administration:

P.o. 1 h before the stab wound injury
Result:

Inhibited the L-PGDS reaction in the brain.
Decreased the total amount of PGD₂ in the brain to 40% with 30 mg/kg AT-56.

Animal Model:

Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g)^[1]
Dosage:

0, 1, 10 mg/kg
Administration:

P.o. 1 h before and 24 h after the antigen exposure
Result:

Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS.

Animal Model:

Male C57BL/6 mice (7 weeks, 22-26 g)^[1]
Dosage:

10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis)
Administration:

P.o. and i.v. administration
Result:

Oral bioavailability (82%); C_max (2.15 μg/ml); T_1/2 (1.71 h, p.o.); T_1/2 (2.35 h, i.v.).

Chemical Information

CAS. Nr. 162640-98-4
Appearance Solid
Molecular Weight 397.52
Formel C₂₅H₂₇N₅
Color White to off-white
SMILES

N1(CCCCC2=NNN=N2)CC/C(CC1)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All RT-PCRCell Migration/Invasion AssayIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Rheumatology (Oxford)

Targeting PTGDS inhibits pro-inflammatory fibroblasts against skin fibrosis in systemic sclerosis. [Abstract]

2025 Oct 1;64(10):5551-5561. PMID: 40478772

AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]

The mRNA levels of chemokines in PTGDS-overexpressed (PTGDS-OE) BJ cells with or without AT56 treatment (150 μM) were analysed by RT-PCR.

AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]

Flow chart of the Transwell migration assay upon control BJ cells, PTGDS-OE BJ cells with or without AT56 treatment (150 μM) co-cultured with PBMC or T lymphocytes.

AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]

The SSc skin fibrosis model was established by s.c. injection of BLM (7.5 mg/kg) every other day for 2 weeks. BLM-treated mice were administered daily with either AT56 (10 mg/kg or 30 mg/kg) or vehicle from day 1–14 and were analysed on day 14.

AT-56 purchased from MedChemExpress. Usage Cited in: Rheumatology (Oxford). 2025 Oct 1;64(10):5551-5561. [Abstract]

Representative skin sections with H&E staining, Masson's trichrome staining, and immunohistochemical staining for α-SMA and CD4 in the PBS-treated control mice, and the BLM-induced skin fibrosis mice treated with either vehicle, 10 mg/kg AT56, or 30 mg/kg AT56. Scale bar, 250 μm or 50 μm.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (251.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5156 mL

12.5780 mL

25.1560 mL

5 mM

0.5031 mL

2.5156 mL

5.0312 mL

10 mM

0.2516 mL

1.2578 mL

2.5156 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Irikura D, et, al. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem. 2009 Mar 20; 284(12): 7623-30. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5156 mL	12.5780 mL	25.1560 mL	62.8899 mL
	5 mM	0.5031 mL	2.5156 mL	5.0312 mL	12.5780 mL
	10 mM	0.2516 mL	1.2578 mL	2.5156 mL	6.2890 mL
	15 mM	0.1677 mL	0.8385 mL	1.6771 mL	4.1927 mL
	20 mM	0.1258 mL	0.6289 mL	1.2578 mL	3.1445 mL
	25 mM	0.1006 mL	0.5031 mL	1.0062 mL	2.5156 mL
	30 mM	0.0839 mL	0.4193 mL	0.8385 mL	2.0963 mL
	40 mM	0.0629 mL	0.3144 mL	0.6289 mL	1.5722 mL
	50 mM	0.0503 mL	0.2516 mL	0.5031 mL	1.2578 mL
	60 mM	0.0419 mL	0.2096 mL	0.4193 mL	1.0482 mL
	80 mM	0.0314 mL	0.1572 mL	0.3144 mL	0.7861 mL
	100 mM	0.0252 mL	0.1258 mL	0.2516 mL	0.6289 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AT-56

Orally Active Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Immunology/Inflammation Compound Library

Publications Citing Use of MedChemExpress (MCE) AT-56

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AT-56

Orally Active Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Immunology/Inflammation Compound Library

Publications Citing Use of MedChemExpress (MCE) AT-56

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AT-56 Related Classifications

HY-13988 Related Classifications